Clinical Trials on Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor in Switzerland

Total 1 results

AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia

3

Subscribe